Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154294 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
A Phase 1 study, sponsored by Avera McKennan Hospital & University Health Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03154294 is a Phase 1 study that has completed, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 19 participants.
The verdict
NCT03154294, a Phase 1 study, has completed, sponsored by Avera McKennan Hospital & University Health Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is an open-label, cohort study to determine the feasibility and tolerability of the combination of TAK-228 and TAK-117 given on days 2-4, 9-11, 16-18, and 23-25 with paclitaxel on days 1, 8, and 15 for one 28-day cycle in patients with advanced solid tumors.
Interventions
- DRUG paclitaxel
- DRUG TAK-228
- DRUG TAK-117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2022-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03154294
The ClinicalTrials.gov registry entry for NCT03154294 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avera McKennan Hospital & University Health Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT03154294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03154294 about?
NCT03154294 is a clinical study titled "Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors". This is an open-label, cohort study to determine the feasibility and tolerability of the combination of TAK-228 and TAK-117 given on days 2-4, 9-11, 16-18, and 23-25 with paclitaxel on days 1, 8, and 15 for one 28-day cycle in patients with advanced solid tumors.
What is the current status of trial NCT03154294?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2017-07-06. Estimated completion is 2022-11-20.
What interventions are being tested in trial NCT03154294?
The interventions under investigation include: paclitaxel (DRUG), TAK-228 (DRUG), TAK-117 (DRUG).
Who is sponsoring clinical trial NCT03154294?
This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.